IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study

@inproceedings{Suppiah2011IL28BHA,
  title={IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study},
  author={Vijayaprakash Suppiah and Silvana Gaudieri and Nicola J Armstrong and K. O'Connor and Thomas Berg and Martin D Weltman and Maria Lorena Abate and Ulrich Spengler and Margaret Fiona Bassendine and Gregory J Dore and William Lucien Irving and Elizabeth A. Powell and Margaret Hellard and Stephen Riordan and Gail Matthews and David A Sheridan and Jacob Nattermann and Antonina Smedile and Tobias Carsten M{\"u}ller and Emma L Hammond and David Dunn and F. de Toro Negro and Pierre-Yves Bochud and Simon A Mallal and Golo Ahlenstiel and Graeme John Stewart and Jacob George and David M. Booth},
  booktitle={PLoS medicine},
  year={2011}
}
BACKGROUND To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined… CONTINUE READING